Business
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire /
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (\"Ensysce\" or the \"Company\"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled: Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof¹ including both composition of matter and method of use claims. PF9001, the innovative medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce's TAAPTM and MPAR® abuse deterrent and overdose protection technologies.Methadone has long been a cornerstone treatment for OUD, but its use has been limited by concerns over cardiac side effects, respiratory depression, and risk of overdose. Ensysce has developed a new class of agents for the treatment for OUD in the form of PF9001. This new drug is a significant advancement in the treatment of OUD, with data demonstrating a reduction in potential for cardiotoxicity, validating MPAR® overdose protection, and indications of potentially delivering a prolonged and predictable effect following once daily dosing.Dr. Richard Dart, Director of the Rocky Mountain Poison and Drug Center who specializes in emergency medicine and toxicology commented, \"Novel agents for the treatment of OUD are needed. The MPAR technology applied to methadone analogues has the potential to save lives by reducing overdose.\"Dr. Lynn Kirkpatrick, CEO of Ensysce, added, \"PF9001 and this approach is the result of years of dedicated research focused on providing safer medications for the treatment of OUD while reducing the risks associated with its therapy. Our novel TAAP and MPAR technology offers patients and providers a safer, more tolerable alternative to current therapy which has been recognized with financial support provided by the National Institute on Drug Abuse. We believe PF9001 could potentially increase treatment adherence and improve outcomes for OUD patients.\"¹The research covered by this patent was supported by the National Institute on Drug Abuse o...